Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

被引：18
|
作者：
Powles, Thomas
Choueiri, Toni K.
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Motzer, Robert J.
机构：
[1] Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Bradford Hill Clin Res Ctr, Santiago, Chile
[5] Gustave Roussy, Villejuif, France
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Vall dHebron Barcelona Hosp Campus, Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Ist Toscano Tumori, Osped San Donato, Arezzo, Italy
[10] Univ Pavia, Pavia, Italy
[11] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia
[12] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[13] Westmead Hosp, Sydney, NSW, Australia
[14] Macquarie Univ Hosp, Sydney, NSW, Australia
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhand Karls Univ Tubingen, Tubingen, Germany
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Exelixis Inc, Alameda, CA USA
[19] NCI, NIH, Bethesda, MD 20892 USA
[20] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：4
相关论文
共 47 条
  • [21] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
  • [22] Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Burotto, Mauricio
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 63 - 71
  • [23] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Motzer, R. J.
    Powles, T.
    Burotto, M.
    LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319
  • [24] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Vergote, I
    Gonzalez-Martin, A.
    Lorusso, D.
    LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
  • [25] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
    Choueiri, Toni K.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Aren, Osvaldo Rudy
    Shah, Amishi
    Kessler, Elizabeth Riley
    Hsieh, James J.
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Plimack, E. R.
    Porta, C. G.
    George, S.
    Powles, T. B.
    Donskov, F.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M-O.
    Tomita, Y.
    Rini, B. I.
    McHenry, M. B.
    Lee, C-W.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
  • [27] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [28] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Grimm, M. -O.
    Tannir, N.
    McDermott, D.
    Escudier, B.
    Hammers, H.
    Aren Frontera, O.
    Plimack, E.
    Barthelemy, P.
    Neiman, V.
    George, S.
    Porta, C.
    Powles, T.
    Donskov, F.
    Amin, A.
    Tykodi, S.
    Tomita, Y.
    Rini, B.
    McHenry, M. B.
    Saggi, S. S.
    Motzer, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
  • [29] Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Tannir, Nizar M.
    McDermott, David F.
    Escudier, Bernard
    Hammers, Hans J.
    Aren, Osvaldo Rudy
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Neiman, Victoria
    George, Saby
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    Grimm, Marc-Oliver
    Amin, Asim
    Tykodi, Scott S.
    Tomita, Yoshihiko
    Rini, Brian I.
    McHenry, M. Brent
    Saggi, Shruti Shally
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    ESMO OPEN, 2020, 5 (06)
12345